Literature DB >> 12885922

Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Hector R Rangel1, Jan Weber, Bikram Chakraborty, Arantxa Gutierrez, Michael L Marotta, Muneer Mirza, Patti Kiser, Miguel A Martinez, Jose A Este, Miguel E Quiñones-Mateu.   

Abstract

A human host offers a variety of microenvironments to the infecting human immunodeficiency virus type 1 (HIV-1), resulting in various selective pressures, most of them directed against the envelope (env) gene. Therefore, it seems evident that the replicative capacity of the virus is largely related to viral entry. In this study we have used growth competition experiments and TaqMan real-time PCR detection to measure the fitness of subtype B HIV-1 primary isolates and autologous env-recombinant viruses in order to analyze the contribution of wild-type env sequences to overall HIV-1 fitness. A significant correlation was observed between fitness values obtained for wild-type HIV-1 isolates and those for the corresponding env-recombinant viruses (r = 0.93; P = 0.002). Our results suggest that the env gene, which is linked to a myriad of viral characteristics (e.g., entry into the host cell, transmission, coreceptor usage, and tropism), plays a major role in fitness of wild-type HIV-1. In addition, this new recombinant assay may be useful for measuring the contribution of HIV-1 env to fitness in viruses resistant to novel antiretroviral entry inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885922      PMCID: PMC167250          DOI: 10.1128/jvi.77.16.9069-9073.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  New targets for inhibitors of HIV-1 replication.

Authors:  J P Moore; M Stevenson
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

Review 2.  Implications of antiretroviral resistance on viral fitness.

Authors:  M Nijhuis; S Deeks; C Boucher
Journal:  Curr Opin Infect Dis       Date:  2001-02       Impact factor: 4.915

3.  CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro.

Authors:  J Blanco; J Barretina; C Cabrera; A Gutiérrez; B Clotet; J A Esté
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

4.  Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.

Authors:  M Cabana; B Clotet; M A Martínez
Journal:  J Med Virol       Date:  1999-12       Impact factor: 2.327

5.  Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda.

Authors:  Pontiano Kaleebu; Neil French; Cedric Mahe; David Yirrell; Christine Watera; Fred Lyagoba; Jessica Nakiyingi; Alleluiah Rutebemberwa; Dilys Morgan; Jonathan Weber; Charles Gilks; Jimmy Whitworth
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

6.  Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.

Authors:  J A Esté; C Cabrera; J Blanco; A Gutierrez; G Bridger; G Henson; B Clotet; D Schols; E De Clercq
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 7.  Potential new therapies for the treatment of HIV-1 infection.

Authors:  Jon H Condra; Michael D Miller; Daria J Hazuda; Emilio A Emini
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

8.  A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Authors:  M E Quiñones-Mateu; S C Ball; A J Marozsan; V S Torre; J L Albright; G Vanham; G van Der Groen; R L Colebunders; E J Arts
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Authors:  Miguel E Quiñones-Mateu; Mahlet Tadele; Mariona Parera; Antonio Mas; Jan Weber; Héctor R Rangel; Bikram Chakraborty; Bonaventura Clotet; Esteban Domingo; Luis Menéndez-Arias; Miguel A Martínez
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS.

Authors:  Shan-Lu Liu; John E Mittler; David C Nickle; Thera M Mulvania; Daniel Shriner; Allen G Rodrigo; Barry Kosloff; Xi He; Lawrence Corey; James I Mullins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

View more
  44 in total

1.  Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity.

Authors:  Vanessa L Naidoo; Jaclyn K Mann; Christie Noble; Emily Adland; Jonathan M Carlson; Jake Thomas; Chanson J Brumme; Christina F Thobakgale-Tshabalala; Zabrina L Brumme; Mark A Brockman; Philip J R Goulder; Thumbi Ndung'u
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.

Authors:  Philippe Selhorst; Carina Combrinck; Nonkululeko Ndabambi; Sherazaan D Ismail; Melissa-Rose Abrahams; Miguel Lacerda; Natasha Samsunder; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.

Authors:  Wuwei Wu; Derek C Blythe; Hyelee Loyd; Robert H Mealey; Rebecca L Tallmadge; Karin S Dorman; Susan Carpenter
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

4.  Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor.

Authors:  Kerry Gordon; Shatha Omar; Andile Nofemela; Gama Bandawe; Carolyn Williamson; Zenda Woodman
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-20       Impact factor: 2.205

5.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

6.  Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

Authors:  Yasuhiro Takeuchi; Myra O McClure; Massimo Pizzato
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Simian immunodeficiency virus variants that differ in pathogenicity differ in fitness under rapid cell turnover conditions.

Authors:  Yegor Voronin; Julie Overbaugh; Michael Emerman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.

Authors:  Filippo Canducci; Maria Chiara Marinozzi; Michela Sampaolo; Stefano Berrè; Patrizia Bagnarelli; Massimo Degano; Giulia Gallotta; Benedetta Mazzi; Philippe Lemey; Roberto Burioni; Massimo Clementi
Journal:  Retrovirology       Date:  2009-01-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.